PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF THE BISPECIFIC T-CELL ENGAGER ANTIBODY BLINATUMOMAB IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA

被引：0
|
作者：
Hijazi, Y. [1 ]
Klinger, M. [1 ]
Schub, A. [1 ]
Wu, B. [2 ]
Zhu, M. [2 ]
Kufer, P. [1 ]
Wolf, A. [1 ]
Nagors-en, D. [3 ]
机构：
[1] Amgen Res Munich GmbH, Munich, Germany
[2] Pharmacokinet & Drug Metab, Thousand Oaks, CA USA
[3] Amgen Inc, Clin Dev, Thousand Oaks, CA 91320 USA
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P306
引用
收藏
页码：131 / 131
页数：1
相关论文
共 50 条
  • [31] An unusual extranodal T-cell non-Hodgkin lymphoma
    Coats, Josh T.
    Mackie, Alasdair D. R.
    Kernohan, Neil M.
    Ramkumar, Prasad Guntur
    McMahon, Lesley M.
    Goodlad, John R.
    Tauro, Sudhir
    LANCET, 2016, 388 (10049): : 1127 - 1128
  • [32] Novel bispecific antibody causes tumor regression in patients with non-Hodgkin lymphoma
    Nature Clinical Practice Oncology, 2008, 5 (12): : 684 - 684
  • [33] Dermatologic Adverse Events in Acute Lymphocytic Leukemia Patients Treated with Bispecific T-Cell Engager Blinatumomab
    Parisi, Rose
    Cowen, Emily A.
    Gu, Stephanie
    Pulitzer, Melissa
    Geyer, Mark B.
    King, Amber C.
    Markova, Alina
    BLOOD, 2022, 140 : 11583 - 11583
  • [34] Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab
    Parisi, Rose
    Cowen, Emily A.
    Gu, Stephanie
    Dusza, Stephen
    Pulitzer, Melissa
    Geyer, Mark B.
    King, Amber C.
    Markova, Alina
    LEUKEMIA & LYMPHOMA, 2023,
  • [35] Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease
    Ali, Sahra
    Moreau, Alexandre
    Melchiorri, Daniela
    Camarero, Jorge
    Josephson, Filip
    Olimpier, Odoardo
    Bergh, Jonas
    Karres, Dominik
    Tzogani, Kyriaki
    Gisselbrecht, Christian
    Pignatti, Francesco
    ONCOLOGIST, 2020, 25 (04): : E709 - E715
  • [36] MODELING THE PHARMACOKINETIC/PHARMACODYNAMIC PLATELET RESPONSE OF INOTUZUMAB OZOGAMICIN, A NOVEL ANTIBODY DRUG CONJUGATE, ADMINISTERED ALONE OR IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA
    Boni, J.
    Garcia, A. Ruiz
    Liao, S.
    Mugundu, G.
    Vandendries, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 355 - 355
  • [37] Blinatumomab: a novel therapy for the treatment of non-Hodgkin?s lymphoma
    Bukhari, Ali
    Lee, Seung Tae
    EXPERT REVIEW OF HEMATOLOGY, 2019, 12 (11) : 909 - 918
  • [38] CATHEPSIN S PROTEASE MEDIATES T-CELL RESPONSE IN NON-HODGKIN LYMPHOMA
    不详
    CANCER DISCOVERY, 2020, 10 (06) : 761 - 761
  • [39] Peripheral T-cell non-Hodgkin's lymphoma NOS: naming of parts
    M J S Dyer
    R Siebert
    Leukemia, 2006, 20 : 208 - 209
  • [40] Aggressive non-Hodgkin's lymphoma: T-cell versus B-cell
    Liang, R
    Todd, D
    Ho, FCS
    HEMATOLOGICAL ONCOLOGY, 1996, 14 (01) : 1 - 6
12345